Accepted Posters

Abstract Title	Topic
Algorithmic Approach for Early Diagnosis and Management of Capillary Leak Syndrome (CLS) in Hematologic Malignancies	Acute myeloid leukemia
Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-risk Patients With Relapsed/Refractory and Frontline Acute Myeloid Leukemia (AML)	Acute myeloid leukemia
QuANTUM-First Trial: FLT3-ITD–Specific MRD Clearance Is Associated With Improved Overall Survival	Acute myeloid leukemia
The Prevalence of RUNX1 Gene Alterations in De Novo Adult Acute Myeloid Leukemia Patients	Acute myeloid leukemia
Early Results From the Phase 1b/2 EPCORE CLL-1 Trial: Subcutaneous Epcoritamab in Patients With Richter Syndrome	Chronic lymphocytic leukemia
Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients With Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results From a Phase 2 Pivotal Clinical Trial	Chronic lymphocytic leukemia
Zanubrutinib (Zanu) in Patients (Pts) With B-Cell Malignancies Intolerant to Acalabrutinib (Acala)	Chronic lymphocytic leukemia
Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients (Pts) With Heavily Transfused Non-del(5q) Lower-risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESA) Within the IMerge Phase 2 (Ph2) Trial	Myelodysplastic syndrome
Pacritinib Is a Potent ACVR1 Inhibitor With Significant Anemia Benefit in Patients With Myelofibrosis	Myeloproliferative neoplasms
Initial Results From Phase 1/2 Trial of Subcutaneous Epcoritamab in Combination With Rituximab + Lenalidomide (R2) for First-line Treatment of Follicular Lymphoma	Non-Hodgkin lymphoma
Rate of Cardiac Disorders in Patients (Pts) With B-Cell Malignancies Who Undergo Treatment With Zanubrutinib (Zanu)	Non-Hodgkin lymphoma
Subcutaneous Epcoritamab Monotherapy Leads to Deep, Durable Responses and Minimal Residual Disease Negativity: Novel Subgroup Analyses in Patients With Relapsed/Refractory Large B Cell Lymphoma	Non-Hodgkin lymphoma
Updated Results From a Phase 1/2 Trial of Subcutaneous Epcoritamab With Rituximab + Lenalidomide (R2) in Patients With Relapsed/Refractory Follicular Lymphoma	Non-Hodgkin lymphoma
Preliminary Safety of Bcl-2 Inhibitor BGB-11417 in Relapsed/Refractory Multiple Myeloma Harboring t(11,14): Phase 1b/2 Study	Multiple myeloma
Single-Agent Belantamab Mafodotin in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): Final Analysis of the DREAMM-2 Trial	Multiple myeloma
Impact of Dysgeusia on Transplant Recipients With Refractory Cytomegalovirus With/Without Resistance Receiving Maribavir: Post Hoc Analyses From a Phase 3 Randomized Trial	Other, including preclinical studies
Maribavir vs Investigator-Assigned Therapy for Refractory Cytomegalovirus Infection (with/without resistance) in Hematopoietic Cell Transplant Recipients: Subgroup Safety Analysis of a Phase 3 Study	Other, including preclinical studies
Early Hemoglobin and Transfusion Trends From OPERA: A Real-world Study of Pegcetacoplan Treatment in US Adults With Paroxysmal Nocturnal Hemoglobinuria	Other blood cell disorders, including idiopathic thrombocytopenic purpura
Impact of Pegcetacoplan on Paroxysmal Nocturnal Hemoglobinuria Symptoms in Patients Previously Treated With C5 Inhibitors	Other blood cell disorders, including idiopathic thrombocytopenic purpura
Real-world Experience with Fostamatinib for Treatment of Immune Thrombocytopenia (ITP): Patient-Reported Outcomes	Other blood cell disorders, including idiopathic thrombocytopenic purpura